Company intelligence / Profile preview

CAnDiD Consulting

San Diego, California, USAcandidconsult.org ↗

Ownership: Private
Development stage: Other

Overview

Candid Therapeutics launched with two advanced bispecific antibodies, CND106 (BCMA x CD3) and CD20xCD3 antibody, both of which have completed Phase I trials in oncology patients. These candidates are now being developed for autoimmune disease indications, focusing on selective depletion of B lymphocytes via T cell engagers to improve upon existing therapies like Humira and Rituxan.

Therapeutic areas: ImmunologyNeurology
Modalities: AntibodyBispecific monoclonal antibodyT cell engager antibodies
Industry: Biotech

Beyond the preview

Go deeper on CAnDiD Consulting.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAnDiD Consulting.

Explore the full profile